Padraig Andrew O'Connor
Known title: EVP, Global OperationsCIK: 0002098740
Associated companies
Transaction History
| BSX | ▲ Buy | Option Exercise | 1,171 | $0 | 9/2/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 567 | $27K | 9/2/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,802 | $0 | 5/2/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 872 | $49K | 5/2/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 905 | $0 | 2/16/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 339 | $25K | 2/16/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,190 | $0 | 2/14/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 449 | $34K | 2/14/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 500 | $0 | 2/13/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 199 | $15K | 2/13/2026 | View on chart |
| BSX | ▲ Buy | Option Exercise | 1,058 | $0 | 2/12/2026 | View on chart |
| BSX | ▼ Sell | Tax Withholding | 457 | $34K | 2/12/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate
Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.
Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.